Diamyd Phase IIb trial results published in Diabetes Care
STOCKHOLM, May 21, 2021 /PRNewswire/
Diabetes Care has published the results of DIAGNODE-2, a Phase IIb trial that evaluated intralymphatic administration of Diamyd Medical s lead drug candidate Diamyd (GAD-alum) in individuals recently diagnosed with type 1 diabetes. Results showed, in line with a published large-scale metaanalysis of clinical data, that while no treatment benefit was seen in the full patient population, three intralymphatic injections of Diamyd
had a significant and positive effect on the preservation of insulin producing capacity in the predefined subgroup of individuals that carry the HLA DR3-DQ2 haplotype. In this subgroup of patients, more than 50% greater preservation of insulin producing capacity was observed at 15 months from baseline in those that received active treatment compared to placebo.
Investegate announcements from Nexstim Oyj, Share issue / transfer and annulment of shares in connection with reduction of the quantity of shares in Nexstim Plc
Diamyd® Phase IIb trial results published in Diabetes Care
News provided by
Share this article
STOCKHOLM, May 21, 2021 /PRNewswire/
Diabetes Care has published the results of DIAGNODE-2, a Phase IIb trial that evaluated intralymphatic administration of Diamyd Medical s lead drug candidate Diamyd
® (GAD-alum) in individuals recently diagnosed with type 1 diabetes. Results showed, in line with a published large-scale metaanalysis of clinical data, that while no treatment benefit was seen in the full patient population, three intralymphatic injections of Diamyd
® had a significant and positive effect on the preservation of insulin producing capacity in the predefined subgroup of individuals that carry the HLA DR3-DQ2 haplotype. In this subgroup of patients, more than 50% greater preservation of insulin producing capacity was observed at 15 months from baseline in those that received active treatment compared to placebo.
San Juan Strains Inc Selects Heliospectra s MITRA LED Lighting Solutions
News provided by
Share this article
Heliospectra AB (publ) (North American ADR OTCQB: HLSPY) (Nasdaq First North Growth Market: HELIO)
, a world leader in intelligent lighting technology for greenhouse and controlled plant growth environments, announces a new order from San Juan Strains Inc of Pagosa Springs, Colorado, United States. The order is for Heliospectra s MITRA LED lighting solution and the value is $319,000 USD.
San Juan Strains is a locally owned and operated recreational cannabis business with a large light deprivation greenhouse grow located in Pagosa Springs, Colorado. San Juan Strains specializes in soil and sun grown cannabis flower, and solvent-less cannabis concentrates.
Investegate |CoinShares International Limit Announcements | CoinShares International Limit: CoinShares ETPs Reach Record Trading Volumes investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.